Roche Products (India) and Entero Healthcare Solutions have entered into an agreement to improve access to nephrology medicines.
Under this agreement, Entero will be responsible for the promotion, marketing and distribution of Roche Pharma’s nephrology drugs, Mycophenolate Mofetil (Cellcept), Valganciclovir (Valcyte), Epoetin Beta (NeoRecormon), and Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in India. Entero is backed by OrbiMed, a leading global healthcare investment firm.
Roche Pharma said it was taking multiple steps to increase the reach of its innovations in India. The company has
The company is expanding its presence in different states in India by increasing its field force in a phased manner and investing in new talent in India over the next few months. The partnership deal, the discussions for which have been on for the last few months, will help the company focus on these states and capabilities. Currently, the company has more than 2,000 people working across states and through various partners in India, it said in a statement.
“While we keep working towards creating and enhancing the healthcare ecosystem in India, we need to differentiate between our existing products that can reach the patients at a faster pace through a valued partnership like this, and the newer innovative drugs that we can focus on bringing into India in the next few years,” said V Simpson Emmanuel, General Manager, Roche Products (India).